Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Mayzent

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

- PMLiVE

Genzyme continues MS drug rollout across EU

Lemtrada and Aubagio now available in Republic of Ireland

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

Biogen Idec building

Final NICE backing for Biogen Idec’s Tecfidera

Oral multiple sclerosis is cleared for NHS use in England

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

Biogen Idec building

FDA approves Biogen Idec’s long-acting MS therapy

Plegridy gets US nod just weeks after EU approval

- PMLiVE

Rebif hit again as competition bites

Merck Serono’s MS drug continues its struggle for sales in the US and Europe

Novartis building

Novartis will file heart failure drug before year-end

New data reinforces view that LCZ696 can reduce cardiovascular deaths

MS market set to grow 4% annually

Predictedto reach $20bn by 2023 partly due to Plegridy and ocrelizumab launches

Novartis building

Novartis: novel antimalarial is ‘game-changing’

Says cipargamin could be first new class of malaria drugs in 20 years

Novartis building

Novartis’ glaucoma combo cleared in Europe

Simbrinza approved to treat eye condition

Biogen Idec building

Plegridy approval underlines Biogen Idec’s dominance in MS

And Tecfidera boosts pharma company’s second quarter financial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links